IL-7 is a member of the common γ -chain family of cytokines sharing a common γ -chain in their receptor. Beyond its long-established pivotal role in immune development, it has been more recently recognized as a critically important regulator of peripheral naïve and memory T cell homeostasis while its role in postdevelopment thymic function remains at best, poorly defined, and controversial. Its multiple immune-enhancing properties, most notably in the maintenance of T cell homeostasis, make it a very attractive candidate for immunotherapy in a wide variety of clinical situations. Following many years of rich preclinical data in murine and simian models, IL-7 is now emerging in human phase I trials as a very promising immunotherapeutic agent. Human in vivo data discussed here are derived from the phase I study initiated at the National Cancer Institute in collaboration with Cytheris, Inc., in a cohort of subjects with incurable malignancy. © 2007 Springer Science+Business Media, LLC.
CITATION STYLE
Sportès, C., & Gress, R. E. (2007). Interleukin-7 immunotherapy. In Advances in Experimental Medicine and Biology (Vol. 601, pp. 321–333). https://doi.org/10.1007/978-0-387-72005-0_35
Mendeley helps you to discover research relevant for your work.